Amylin analog pramlintide induces migraine-like attacks in patients

Published on Mar 27, 2021in Annals of Neurology9.037
· DOI :10.1002/ANA.26072
Hashmat Ghanizada6
Estimated H-index: 6
(UCPH: University of Copenhagen),
Mohammad Al-Mahdi Al-Karagholi7
Estimated H-index: 7
(UCPH: University of Copenhagen)
+ 17 AuthorsMessoud Ashina65
Estimated H-index: 65
(UCPH: University of Copenhagen)
Sources
Abstract
Objective Migraine is a prevalent and disabling neurological disease. Its genesis is poorly understood and there remains unmet clinical need. We aimed to identify mechanisms and thus novel therapeutic targets for migraine using human models of migraine and translational models in animals, with emphasis on amylin, a close relative of calcitonin gene-related peptide (CGRP). Methods Thirty-six migraine without aura patients were enrolled in a randomized, double-blinded, two-way, cross-over, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on two different experimental days. Furthermore, translational studies in cells and mouse models, and rat and human tissue samples were conducted. Results Thirty patients (88%) developed headache after pramlintide infusion, compared to thirty-three (97%) after CGRP (p = 0.375). Fourteen patients (41%) developed migraine-like attacks after pramlintide infusion, compared to nineteen patients (56%) after CGRP (p = 0.180). The pramlintide induced migraine-like attacks had similar clinical characteristics to those induced by CGRP. There were differences between treatments in vascular parameters. Human receptor pharmacology studies showed that an amylin receptor likely mediates these pramlintide-provoked effects, rather than the canonical CGRP receptor. Supporting this, preclinical experiments investigating symptoms associated with migraine showed that amylin treatment, like CGRP, caused cutaneous hypersensitivity and light aversion in mice. Interpretation Our findings propose amylin receptor agonism as a novel contributor to migraine pathogenesis. Greater therapeutic gains could therefore be made for migraine patients through dual amylin and CGRP receptor antagonism, rather than selectively targeting the canonical CGRP receptor. This article is protected by copyright. All rights reserved.
📖 Papers frequently viewed together
16 Citations
20 Citations
References49
Newest
#1Messoud AshinaH-Index: 65
#2Dawn C. Buse (Albert Einstein College of Medicine)H-Index: 53
Last. David W. Dodick (Mayo Clinic)H-Index: 94
view all 12 authors...
Summary Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ between countries and include acute, preventive, and non-pharmacological therapies. Because of major progress in the understanding of migraine pathogenesis, novel mechanism-based medications have emerged and expanded the armamentarium of treatments. We provide a comprehensive overview of the current standard of care that will enable info...
6 CitationsSource
#1Messoud AshinaH-Index: 65
#2Zaza Katsarava (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 1
Last. Richard B. Lipton (Albert Einstein College of Medicine)H-Index: 178
view all 15 authors...
Summary Migraine is a neurovascular disorder that affects over 1 billion people worldwide. Its widespread prevalence, and associated disability, have a range of negative and substantial effects not only on those immediately affected but also on their families, colleagues, employers, and society. To reduce this global burden, concerted efforts are needed to implement and improve migraine care that is supported by informed health-care policies. In this Series paper, we summarise the data on migrai...
8 CitationsSource
#2William C. Castonguay (UI: University of Iowa)H-Index: 2
Last. Andrew F. RussoH-Index: 46
view all 12 authors...
ABSTRACT Chronic complications of traumatic brain injury represent one of the greatest financial burdens and sources of suffering in the society today. A substantial number of these patients suffer from posttraumatic headache (PTH), which is typically associated with tactile allodynia. Unfortunately, this phenomenon has been understudied, in large part because of the lack of well-characterized laboratory animal models. We have addressed this gap in the field by characterizing the tactile sensory...
4 CitationsSource
#1Hashmat Ghanizada (UCPH: University of Copenhagen)H-Index: 6
#2Afrim Iljazi (UCPH: University of Copenhagen)H-Index: 6
Last. Messoud Ashina (UCPH: University of Copenhagen)H-Index: 65
view all 7 authors...
BackgroundHuman models of migraine have been used for the past 30 years to test putative ‘trigger’ molecules and ascertain whether they induce migraine attacks in humans. However, nocebo effects us...
5 CitationsSource
#1Hannah Louise Zakariassen (UCPH: University of Copenhagen)H-Index: 1
#2Linu M. John (Novo Nordisk)H-Index: 5
Last. Christelle Le Foll (UZH: University of Zurich)H-Index: 19
view all 10 authors...
Abstract The amylin receptor (AMY) and calcitonin receptor (CTR) agonists induce acute suppression of food intake in rodents by binding to receptors in the area postrema (AP) and potentially by targeting arcuate (ARC) neurons directly. Salmon calcitonin (sCT) induces more potent, longer lasting anorectic effects compared to amylin. We thus aimed to investigate whether AMY/CTR agonists target key neuronal populations in the ARC, and whether differing brain distribution patterns could mediate the ...
10 CitationsSource
#1Anthony P. Davenport (University of Cambridge)H-Index: 83
#2Conor C G ScullyH-Index: 1
Last. Janet J. Maguire (University of Cambridge)H-Index: 47
view all 5 authors...
Wellcome Trust [WT107715/Z/15/Z], Cambridge Biomedical Research Centre Biomedical Resources Grant
39 CitationsSource
#1Lars Edvinsson (Lund University)H-Index: 115
#2Anne Sofie Grell (Glostrup Hospital)H-Index: 3
Last. Karin Warfvinge (Lund University)H-Index: 27
view all 3 authors...
The calcitonin gene-related peptide (CGRP) family of neuropeptides, consists of CGRP, adrenomedullin, amylin, and calcitonin. The receptors consist of either calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) which for function needs an accessory protein, receptor activity-modifying proteins (RAMPs). CGRP has a pivotal role in primary headaches but the role of the other members of the CGRP family of peptides in headaches is not known. Here, we describe the expression of these m...
8 CitationsSource
#1Hashmat Ghanizada (UCPH: University of Copenhagen)H-Index: 6
#2Mohammad Al-Mahdi Al-Karagholi (UCPH: University of Copenhagen)H-Index: 7
Last. Messoud Ashina (UCPH: University of Copenhagen)H-Index: 65
view all 5 authors...
IntroductionPituitary adenylate cyclase-activating polypeptide (PACAP) is found in two functional isoforms, namely PACAP38 and PACAP27. The migraine-inducing properties of PACAP38 are well studied....
25 CitationsSource
#1Mohammad Al-Mahdi Al-Karagholi (UCPH: University of Copenhagen)H-Index: 7
#2Hashmat Ghanizada (UCPH: University of Copenhagen)H-Index: 6
Last. Messoud Ashina (UCPH: University of Copenhagen)H-Index: 65
view all 8 authors...
BACKGROUND: ATP-sensitive potassium (KATP ) channel opener levcromakalim induces migraine attacks in migraine patients. Underlying mechanisms responsible for headache and migraine induction after levcromakalim infusion are unknown. OBJECTIVE: To investigate the effect of levcromakalim on the cranial arteries and to explore the possible relationship between the middle meningeal artery (MMA) dilation and headache. METHODS: In a double-blind, randomized, placebo-controlled study, 20 healthy volunte...
13 CitationsSource
#1Tessa de Vries (EUR: Erasmus University Rotterdam)H-Index: 2
#2Antoinette MaassenVanDenBrink (EUR: Erasmus University Rotterdam)H-Index: 30
A new study shows that the monoclonal antibody fremanezumab is effective for migraine prophylaxis, even in patients who have failed to respond to multiple preventive treatments. However, not all patients benefit from this treatment, and detailed investigation of non-responders could help to identify additional pharmacological targets and increase the number of responders.
9 CitationsSource
Cited By6
Newest
#1Tayla Rees (University of Auckland)H-Index: 3
#2Erica R. Hendrikse (University of Auckland)H-Index: 5
Last. Christopher S. Walker (University of Auckland)H-Index: 18
view all 4 authors...
The calcitonin gene-related peptide (CGRP) system has emerged as a key pharmacological target for the treatment of migraine. However, some individuals who suffer from migraine have low or no response to anti-CGRP or other treatments, suggesting the need for additional clinical targets. CGRP belongs to the calcitonin family of peptides, including calcitonin, amylin, adrenomedullin and adrenomedullin 2. These peptides display a range of pro- and anti-nociceptive actions, including in primary heada...
Source
#1T.P. Do (UCPH: University of Copenhagen)
#2A. Al-Saoudi (UCPH: University of Copenhagen)
Last. M. Ashina (UCPH: University of Copenhagen)
view all 3 authors...
Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepants), are today approved for migraine prophylaxis with additional compounds expected to be introduced to the market soon. In this review, we consider other putative prophylactic migraine drugs in develo...
Source
Source
#1Michael L. Garelja (University of Otago)
#2Christopher S. Walker (University of Auckland)H-Index: 18
Last. Debbie L. Hay (University of Auckland)H-Index: 43
view all 3 authors...
The development of several drugs that target the calcitonin gene-related peptide (CGRP) system has been a major breakthrough in the pharmacological management of migraine. These are divided into two major classes: antibodies which bind to the CGRP peptide, preventing it from activating CGRP receptors and receptor antagonists. Within the receptor antagonist class, there are two mechanisms of action: small molecule receptor antagonists and an antibody antagonist. This mini-review considers the pha...
Source
#1Brandon J. Rea (Roy J. and Lucille A. Carver College of Medicine)H-Index: 4
#2Levi P. Sowers (Roy J. and Lucille A. Carver College of Medicine)H-Index: 10
Last. Andrew F. Russo (Roy J. and Lucille A. Carver College of Medicine)H-Index: 46
view all 8 authors...
We developed an automated squint assay using both black C57BL/6J and white CD1 mice that measured the interpalpebral fissure area between the upper and lower eyelids as an objective quantification of pain. In C57BL/6J mice, we observed a squint response to increasing doses of a migraine trigger, the neuropeptide CGRP, including a significant response in female mice at a dose below detection by the manual grimace scale. Using the automated software, both C57BL/6J and CD1 mice lacked a detectable ...
1 CitationsSource
#1Tayla Rees (University of Auckland)H-Index: 3
#2Debbie L. Hay (University of Otago)H-Index: 43
Last. Christopher S. Walker (University of Auckland)H-Index: 18
view all 3 authors...
Amylin is a 37 amino acid endocrine hormone secreted from the pancreas in response to nutrient intake, acting centrally to promote meal ending satiation. With many studies linking amylin action to the nervous system, determining the distribution or expression of amylin in the nervous system is critical. However, amylin shares sequence identity and structural homology to the related neuropeptide calcitonin-gene related peptide (CGRP). This creates challenges in identifying selective amylin antibo...
1 CitationsSource